Why the study?
Do angiotensin II subtype-1 receptor antagonists improve hemodynamics, glucose metabolism, and diabetic nephropathy in a genetic rat model of non-insulin-dependent diabetes mellitus?
Do angiotensin II subtype-1 receptor antagonists improve hemodynamics, glucose metabolism, and diabetic nephropathy in a genetic rat model of non-insulin-dependent diabetes mellitus?
In a rat model of type 2 diabetes, angiotensin II subtype-1 receptor antagonism improves blood pressure and proteinuria but does not alter glucose metabolism or glomerular structural lesions.
No takes yet. Share an insight, caveat, or question.
ARB benefits BP/proteinuria in T2D rat model without affecting glucose or lesions; leaves open translation to human diabetic nephropathy.
Yoshinari Uehara (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: